All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
During the Acute Leukemia Forum (ALF) 2021, the ALL Hub spoke to Stephan A. Grupp, Children’s Hospital of Philadelphia, Philadelphia, US. We asked, Why should CAR T-cell therapy be used earlier in ALL?
Why should CAR T-cell therapy be used earlier in ALL?
In this video, Grupp outlines what groups of patients with ALL could benefit from earlier treatment with CAR T-cell infusions.
Novel concepts to target CD22 with CAR T-cell therapy for R/R B-ALL
Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a difficult to treat disease with poor prognosis. Two anti-CD19 chimeric antigen receptor (CAR) T-cell...
Anti-CD22 CAR T-cell potency and toxicity is affected by CD4/CD8 T-cell selection
Despite recent advances made with CD19-targeted immunotherapies, there are limited effective treatment options for patients with B-cell acute lymphoblastic leukemia...
Subscribe to get the best content related to ALL delivered to your inbox